BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the
completion of paradigm™ 2, the first phase 3 trial with a long-acting
FIX derivative, N9-GP (glycopegylated recombinant factor IX), for
haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial
evaluating the safety and efficacy of N9-GP when used for on-demand or
prophylactic treatment in patients with haemophilia B.
Company announcement No 37 / 2013:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE